Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 5/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | MITF | O75030 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10586175 | 0.79 | AKR1C3 (0.75) | AKR1C3FFAR1NPC1RAB9AMITF | |
| SCHEMBL12193426 | 0.79 | ALDH1A1 (0.64) | AKR1C3PPARANPC1RAB9AMITF | |
| SCHEMBL30027786 | 0.79 | ALDH1A1 (0.64) | AKR1C3PPARANPC1RAB9AMITF | |
| Hydrochloric Acid SCHEMBL2497324 | 0.78 | ALDH1A1 (0.62) | AKR1C3PPARANPC1RAB9AMITF | |
| SCHEMBL4604349 | 0.78 | AKR1C3 (0.52) | AKR1C3PPARAFFAR1NPC1RAB9A | |
| SCHEMBL25717164 | 0.77 | AKR1C3 (0.72) | AKR1C3FFAR1NPC1RAB9AMITF | |
| SCHEMBL4603675 | 0.77 | AKR1C3 (0.54) | AKR1C3PPARAFFAR1NPC1RAB9A | |
| SCHEMBL4604968 | 0.77 | AKR1C3 (0.54) | AKR1C3PPARAFFAR1NPC1RAB9A | |
| SCHEMBL4605138 | 0.77 | L3MBTL1 (0.54) | AKR1C3PPARAFFAR1NPC1RAB9A | |
| SCHEMBL11323179 | 0.77 | AKR1C3 (0.61) | AKR1C3PPARAFFAR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743891-A1 | Heterocyclic compounds and methods for modulating CXCR3 function | ChemoCentryx Inc (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1216232-B1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR MODULATING CXCR3 FUNCTION | CHEMOCENTRYX INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060063763-A1 | Compounds and methods for modulating CXCR3 function | CHEMOCENTRYX, INC. | 2006-03-23 | — | — | US | disclosed |
| US-6992084-B2 | Compounds and methods for modulating CXCR3 function | CHEMOCENTRYX, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20030119854-A1 | Compounds and methods for modulating CXCR3 function | CHEMOCENTRYX, INC. (US) | 2003-06-26 | — | — | US | disclosed |
| US-6559160-B1 | These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, | CHEMOCENTRYX, INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1216232-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR MODULATING CXCR3 FUNCTION | Chemocentryx, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001016114-A2 | HETEROCYCLIC COMPOUNDS AND METHODS FOR MODULATING CXCR3 FUNCTION | CHEMOCENTRYX, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063763-A1 | Compounds and methods for modulating CXCR3 function | CXCR3, CXCL10, CCR5 | AKR1C3 2640/4885PPARA 367/4885FFAR1 306/4885 |
| US-20030119854-A1 | Compounds and methods for modulating CXCR3 function | CXCR3, CXCL10, CCR5 | AKR1C3 2640/4885PPARA 367/4885FFAR1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.